Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194593 | 0.86 | SYK (0.63) | MRGPRX4RAB9ASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL14854821 | 0.86 | MRGPRX4 (0.55) | MRGPRX4RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL6827590 | 0.85 | MRGPRX4 (0.64) | MRGPRX4MAOB | |
| SCHEMBL5659691 | 0.84 | MAOB (0.58) | RAB9ASMN1; SMN2MAOBGAAMAPT | |
| SCHEMBL11360859 | 0.83 | NPC1 (0.56) | MRGPRX4RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL14855309 | 0.83 | CCR5 (0.52) | MRGPRX4RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL14854665 | 0.83 | MRGPRX4 (0.48) | MRGPRX4RAB9ASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL31193398 | 0.83 | MAOB (0.56) | MRGPRX4RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL14855243 | 0.83 | MRGPRX4 (0.48) | MRGPRX4RAB9ASMN1; SMN2NPC1NFKB1 | |
| SCHEMBL3320471 | 0.83 | MAOB (0.56) | MRGPRX4RAB9ASMN1; SMN2NPC1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278446-B2 | reacting 4-amino-6-chloro-pyrimidine-5-carbaldehyde with 4-benzyloxy-3-chloro-phenylamine in an aqueous solvent and a catalytic amount of hydrochloric acid, to providw 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carbaldehyde, then oximination with (2-morpholin-4-yl-ethyl)-hydroxylamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | claimed |
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICALS USA, INC. | 2010-08-05 | — | — | US | claimed |
| WO-2010017387-A2 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-11 | — | — | WO | claimed |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | claimed |
| WO-2008073519-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-19 | — | — | WO | claimed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| EP-1883631-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | Wyeth (US) | 2008-02-06 | — | — | EP | claimed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | claimed |
| WO-2006127207-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | WYETH (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | WYETH (US) | 2006-11-30 | — | — | US | claimed |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-11-16 | — | — | US | claimed |
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | UNIVERSITY OF KANSAS (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| EP-0113922-A2 | Process for the manufacture of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113920-A2 | Process for the manufacture of stable solutions of cationic methine dyes, and their use in spin dyeing | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113921-A2 | Process for the manufacture of stable solutions of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| US-3956264-A | Basic azo dyestuffs having indolyl-methyleneamino substituent in the diazo component | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | ERBB2, ABL1, EGFR | MRGPRX4 3984/4885RAB9A 2886/4885SMN1; SMN2 4220/4885 |
| US-20240067600-A1 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | MTCH2, TIMM50, TIMM10 | MRGPRX4 3781/4885RAB9A 1640/4885SMN1; SMN2 3138/4885 |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | AREG, TGFB1, TGFB2 | MRGPRX4 1168/4885RAB9A 4747/4885SMN1; SMN2 3890/4885 |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | HCCS, CYP3A7, QPCT | MRGPRX4 2354/4885RAB9A 2459/4885SMN1; SMN2 3385/4885 |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MRGPRX4 2008/4885RAB9A 4709/4885SMN1; SMN2 4172/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | MRGPRX4 2841/4885RAB9A 3795/4885SMN1; SMN2 1033/4885 |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | DHPS, DPYD, DCPS | MRGPRX4 4027/4885RAB9A 4505/4885SMN1; SMN2 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.